tiprankstipranks
Analyst Profile
Followed by 18 other investors
.
Justin Walsh

Justin Walsh

JonesTrading
Wall Street Analyst
Ranked #7,959 out of 8,047 Analysts on TipRanks (#21,099 out of 21,521 overall experts)

Success Rate

23%
13 out of 57 Profitable Transactions

Average Return

-34.10%
Average return per transaction
Time Frame
1 Year
Compare to
No Benchmark
If you copied Justin Walsh's ratings since 2021 and opened each position for the duration of 1 Year:
22.81% of your transactions would have been profitable with an average return of -34.1%

Stock Rating Distribution

68Ratings
95.59% Buy
4.41% Hold
0.00% Sell
Distribution of Justin Walsh's ratings

Additional Information

Main Sector:General
Geo Coverage:
United StatesUS Market

Best Rating

Stock:
Compass Therapeutics, Inc.
(CMPX)
Rating Type:Buy
Dates:Mar 22, 2022 - Jan 01, 1970
Gain:117.30%
The most profitable rating made by Justin Walsh

Justin Walsh's Stock Coverage

Company Name
Date
Position
Action
Price Target
Success Rate
Avg Return
No. of Ratings
Geron
Buy
Initiated
$4.00
(70.21% Upside)
0%
-48.20%
1
F-star Therapeutics
Buy
Initiated
$28.00
(330.77% Upside)
0%
-44.70%
1
Portage Biotech Inc
Buy
Initiated
$40.00
(418.81% Upside)
0%
-64.70%
1
Fusion Pharmaceuticals
Buy
Reiterated
$17.00
(694.39% Upside)
0%
-70.83%
3
Syndax Pharmaceuticals
Buy
Reiterated
$30.00
(25.00% Upside)
60%
+5.58%
5
Precigen
Hold
Assigned
0%
-53.25%
3
EDAP TMS
Hold
Assigned
100%
+3.10%
2
Viewray
Buy
Upgraded
$7.00
(88.68% Upside)
0%
-25.80%
2
Checkpoint Therapeutics
Buy
Reiterated
$18.00
(1284.62% Upside)
0%
-55.15%
2
Eton Pharmaceuticals
Buy
Reiterated
$10.00
(243.64% Upside)
0%
-37.30%
2
List of latest recommendations made by Justin Walsh. Click to expand and see Justin Walsh's performance on a particular stock
Disclaimer: TipRanks collects ratings and price targets of analysts by scanning publicly available reports on financial websites and by receiving reports directly from the analysts or from our users. The information displayed and the Analyst Profile statistics might not be accurate, complete, or up to date. The analyst ratings provided are entirely at the sole responsibility of the of the source publication. TipRanks holds no liability over the analysts' information, price targets, ratings or opinions expressed on the site.
Are We Missing a Rating?
Send us the equity research you are getting and become a Power User
Learn More